R. Stern

发表

Erythromycin Coadministration Increases Plasma Atorvastatin Concentrations

S. Olson, P. Siedlik, B. Yang, 1999, Journal of clinical pharmacology.

Atorvastatin Coadministration May Increase Digoxin Concentrations by Inhibition of Intestinal P‐Glycoprotein‐Mediated Secretion

B. H. Stewart, R. Boyd, R. Stern, 2000, Journal of clinical pharmacology.

Improving the Presentation and Understanding of Risk Models

H. Gurm, R. Stern, D. Smith, 2015, 1504.05138.

Avasimibe Induces CYP3A4 and Multiple Drug Resistance Protein 1 Gene Expression through Activation of the Pregnane X Receptor

J. Sahi, Hongbing Wang, M. Milad, 2003, Journal of Pharmacology and Experimental Therapeutics.

Autosomal dominant inheritance of a predisposition to thoracic aortic aneurysms and dissections and intracranial saccular aneurysms

S. Shete, D. Milewicz, D. Guo, 2011, American journal of medical genetics. Part A.

Individual Risk

R. Stern, 2012, Journal of clinical hypertension.

The Discordance of Individual Risk Estimates and the Reference Class Problem

R. Stern, 2010, 1001.2499.

Renal Dysfunction Does Not Alter the Pharmacokinetics or LDL‐Cholesterol Reduction of Atorvastatin

S. Olson, R. Stern, B-B Yang, 1997, Journal of clinical pharmacology.

The Risk Distribution Curve and its Derivatives

R. Stern, 2009, 0912.3208.

Are risk stratification tables the best way to evaluate model performance?

R. Stern, Dean E. Smith, 2009, Annals of internal medicine.

Effect of Troglitazone on the Pharmacokinetics of an Oral Contraceptive Agent

A. Sedman, R. Stern, C. Loi, 1999, Journal of clinical pharmacology.

Do Risk-Enhancing Factors Enhance Risk Estimation?

R. Brook, R. Stern, 2019, Circulation. Cardiovascular quality and outcomes.

The new hypertension guidelines.

R. Stern, 2013, Journal of clinical hypertension.

Atorvastatin Does Not Alter the Anticoagulant Activity of Warfarin

R. Stern, R. Abel, G. L. Gibson, 1997, Journal of clinical pharmacology.

Are Coagulation Times Biomarkers? Data from a Phase I Study of the Oral Thrombin Inhibitor LB‐30057 (CI‐1028)

K. Criswell, R. Stern, F. Chanoine, 2003, Journal of clinical pharmacology.

Discordance of individual risk estimates.

R. Stern, 2010, Journal of the American College of Cardiology.

Atorvastatin Coadministration May Increase Digoxin Concentrations by Inhibition of Intestinal P‐Glycoprotein‐Mediated Secretion

R. Boyd, R. Stern, E. Reyner, 2000, Journal of clinical pharmacology.

Pharmacodynamics and Pharmacokinetic‐Pharmacodynamic Relationships of Atorvastatin, an HMG‐CoA Reductase Inhibitor

S. Olson, B. Yang, R. Stern, 2000, Journal of clinical pharmacology.

The role of nicotinic acid metabolites in flushing and hepatotoxicity.

R. Stern, 2007, Journal of clinical lipidology.

Nocebo Responses to Antihypertensive Medications

R. Stern, 2008, Journal of clinical hypertension.

Effect of food on the pharmacodynamics and pharmacokinetics of atorvastatin, an inhibitor of HMG-CoA reductase

A. Sedman, R. Stern, L. Whitfield, 2010, European Journal of Drug Metabolism and Pharmacokinetics.

A mutation in the human apolipoprotein A-I gene. Dominant effect on the level and characteristics of plasma high density lipoproteins.

S. Deeb, R. Stern, J. Albers, 1991, The Journal of biological chemistry.

Evolution of mammalian carbonic anhydrase loci by tandem duplication: Close linkage of Car-1 and Car-2 to the centromere region of chromosome 3 of the mouse

T. Roderick, M. Davisson, J. Womack, 1976, Biochemical Genetics.

Effect of Troglitazone on Steady‐State Pharmacokinetics of Digoxin

R. Stern, Artemios B. Vassos, Edward J. Randinitis, 1998, Journal of clinical pharmacology.

Thyroid Status and Carbonic Anhydrase Levels in Mouse Erythrocytes 1

R. Tashian, R. Stern, 1976, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

A human MUTYH variant linking colonic polyposis to redox degradation of the [4Fe4S]2+ cluster

S. Gruber, J. Barton, D. Sherman, 2018, Nature Chemistry.

Differences in metabolism of time-release and unmodified nicotinic acid: explanation of the differences in hypolipidemic action?

J. Spence, R. Stern, D. Freeman, 1992, Metabolism: clinical and experimental.

Tolerance to nicotinic acid flushing

R. Stern, D. Freeman, J. Spence, 1991, Clinical pharmacology and therapeutics.

Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction

R. Stern, L. Whitfield, D. Gibson, 1998, European Journal of Clinical Pharmacology.

Rate of Low‐Density Lipoprotein Cholesterol and Apolipoprotein B Changes on Initiation and Discontinuation of Atorvastatin Treatment

R. Stern, R. Abel, 1997, Journal of clinical pharmacology.

Atorvastatin does not Produce a Clinically Significant Effect on the Pharmacokinetics of Terfenadine

S. Olson, R. Stern, J. Smithers, 1998, Journal of clinical pharmacology.

Problems with modified Framingham Risk Score.

R. Stern, 2014, The Canadian journal of cardiology.

Prognostic models for older adults.

R. Stern, 2012, JAMA.

Evaluating New Cardiovascular Risk Factors for Risk Stratification

Ralph H Stern, R. Stern, 2008, Journal of clinical hypertension.

Left ventricular ejection: Model solution by collocation, an approximate analytical method

R. Stern, H. Rasmussen, 1996, Comput. Biol. Medicine.

Absolute bioavailability of atorvastatin im man

R. Stern, L. Whitfield, D. Gibson, 1997 .

Interpretation of the Area Under the ROC Curve for Risk Prediction Models

R. Stern, 2021, 2102.11053.

A Polygenic Quincunx

R. Stern, 2023, bioRxiv.

Evaluating New Cardiovascular Risk Factors for Risk Stratification

R. Stern, 2008, Journal of clinical hypertension.

Strain distribution and linkage relationship of a mouse embryonic hemoglobin variant

B. Taylor, R. Stern, E. Russell, 1976, Biochemical Genetics.

EFFECTS OF AVASIMIBE ON CYTOCHROME P450 2C9 EXPRESSION IN VITRO AND IN VIVO

J. Sahi, M. Milad, Xianxian Zheng, 2004, Drug Metabolism and Disposition.